

## WEST Search History

DATE: Tuesday, June 24, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR YES; OP OR</i>			
L11	L10 and method and (treat\$ or improv\$ or therap\$)	162	L11
L10	L9 and (corneal epitheli\$)	162	L10
L9	L8 and (integrity or health or differentiat\$ or appear\$)	162	L9
L8	L7 and (sustained release)	163	L8
L7	L6 and retinoid	176	L7
L6	L5 and (contact lens)	1584	L6
L5	L4 and (solution or drops or mist or gel or ointment)	1875	L5
L4	L3 and ophthal\$ and (drug delivery)	2020	L4
L3	L2 and epithel\$	5226	L3
L2	L1 and cornea\$	23522	L2
L1	(retinoi\$ or retino\$ or (vitamin A) or (vit A))	26441103	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptauis3exa

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*

SESSION RESUMED IN FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIC, MEDLINE, BIOSIS, EMBASE' AT 12:53:51 ON 24 JUN 2003

FILE 'CAPLUS' ENTERED AT 12:53:51 ON 24 JUN 2003

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:53:51 ON 24 JUN 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 12:53:51 ON 24 JUN 2003

COPYRIGHT (c) 2003 WILEA Verlag Muenchen (WILEA)

FILE 'JAPIC' ENTERED AT 12:53:51 ON 24 JUN 2003

COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIC

FILE 'MEDLINE' ENTERED AT 12:53:51 ON 24 JUN 2003

FILE 'BIOSIS' ENTERED AT 12:53:51 ON 24 JUN 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (B)

FILE 'EMBASE' ENTERED AT 12:53:51 ON 24 JUN 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.98	25.14

=> s (retino? or vitamin(w)A or Vit(w)A)  
2 FILES SEARCHED...  
3 FILES SEARCHED...  
6 FILES SEARCHED...  
L2 323931 (RETINO? OR VITAMIN.W. A OR VIT(W. A))

=> s l2 and cornea?  
L3 6359 L2 AND CORNEA?

=> s l3 and epitheli?  
L4 2411 L3 AND EPITHELI?

=> s k4 and (drug delivery)  
--- ---User Break---

SEARCH ENDED BY USER

=> s l4 and (drug delivery)  
L5 662 L4 AND (DRUG DELIVERY)

=> s l5 and (drop# or mist or gel or ointment or solution)  
L6 640 L5 AND (DROP# OR MIST OR GEL OR OINTMENT OR SOLUTION)

=> s l6 and (contact lens)  
L7 649 L6 AND (CONTACT LENS)

=> s l7 and epitheli?  
L8 639 L7 AND EPITHELI?

=> s l8 and integrity  
L9 22 L8 AND INTEGRITY

S d 19 1 22

LG ANSWER 1 OF 22 USPATUS COPYRIGHT 2003 AUS  
AN 2002:427371 USPATUS  
DN 147:52346  
TI Method for enhancing integrity of epithelium  
retinoic acid  
IN Lever, Andrea; Smeirbeck, Richard V.  
PA Bausch & Lomb Incorporated, USA  
SO PCT Int. Appl., 13 pp.  
CODEN: PIXXD2  
PT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
- - - - -	- - - - -	- - - - -	- - - - -	- - - - -
PI WO 2002049613	A2	20020627	WO 2001-US46499	20011203
WO 2002049613	A3	20030116		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002032487	A5	20020701	AU 2002-32487	20011203
US 2002115720	A1	20020822	US 2001-23351	20011217
PRAI US 2000-256713P	P	20001219		
WO 2001-US46499	W	20011203		

LG ANSWER 2 OF 22 USPATFULL  
AN 2003:100378 USPATFULL  
TI Method and apparatus for signal transmission and detection using a  
contact device  
IN Abreu, Marcio Marc, North Haven, CT, UNITED STATES  
PI US 2003069489 A1 20030410  
AI US 2002-189779 A1 20020708 (10)  
RLI Continuation of Ser. No. US 2001-827325, filed on 6 Apr 2001, GRANTED,  
Pat. No. US 6423001 Continuation of Ser. No. US 2000-575621, filed on 22  
May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US  
1999-274882, filed on 23 Mar 1999, GRANTED, Pat. No. US 6123668  
Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED,  
Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996 707508,  
filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139  
DT Utility  
FS APPLICATION  
LN.CNT 5863  
INCL INCLM: 600/405.000  
NCL NCLM: 600/405.000  
IC [7]  
ICM: A61B003-16

LG ANSWER 3 OF 22 USPATFULL  
AN 2003:81451 USPATFULL  
TI Use of corneal hardening agents in ophthalmology  
IN Karageozian, Hamper, San Juan Capistrano, CA, United States  
Park, John Y., Santa Ana, CA, United States  
Karageozian, Vicki, San Juan Capistrano, CA, United States  
Baker, Phillip, Walnut Creek, CA, United States

Nesburn, Anthony, Malibu, CA, United States  
PA ISTA Pharmaceuticals, Inc., Irvine, CA, United States (U.S. corporation)  
PI US 6537545 B1 20020305  
AI US 2000-056849 200000907 (9)  
FL Continuation of Ser. No. 09/1899-115115, filed on 3 Mar 1997  
PRAI US 1998-77339P 19980309 (60)  
PT Utility  
FS GRANTED  
LN.CNT 2681  
INCL INCLM: 424/094.400  
INCLS: 424/094.200; 424/094.620; 424/429.000; 424/427.000; 424/078.040  
NCL NCLM: 424/094.400  
NCLS: 424/078.040; 424/094.200; 424/094.620; 424/427.000; 424/429.000  
IC [7]  
ICM: A61K038-44  
EXF 424/422; 424/427; 424/429; 424/94.1; 424/94.2; 424/94.3; 424/94.62;  
424/94.4; 424/78.04; 435/201; 435/183

L9 ANSWER 4 OF 22 USPATFULL  
AN 2002:338063 USPATFULL  
TI Lipoxin analogs as novel inhibitors of angiogenesis  
IN Serhan, Charles N., Needham, MA, UNITED STATES  
Fierro, Iolanda M., Rio de Janeiro, BRAZIL  
PI US 2002193431 A1 20021219  
AI US 2002-86609 A1 20020301 (10)  
PRAI US 2001-272931P 20010302 (60)  
PT Utility  
FS APPLICATION  
LN.CNT 2509  
INCL INCLM: 514/475.000  
NCL NCLM: 514/475.000  
IC [7]  
ICM: A61K031-335  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 22 USPATFULL  
AN 2002:224703 USPATFULL  
TI Methods and compositions for the treatment of keratoconus using protease  
inhibitors  
IN Quay, Steven C., Edmonds, WA, United States  
PA K-Quay Enterprises, LLC, Edmonds, WA, United States (U.S. corporation)  
PI US 6444791 B1 20020903  
AI US 2000-695774 20001024 (9)  
PRAI US 1999-161879P 19991027 (60)  
PT Utility  
FS GRANTED  
LN.CNT 2800  
INCL INCLM: 530/380.000  
INCLS: 530/381.000; 530/412.000; 530/350.000; 514/012.000; 514/912.000;  
424/078.040; 424/094.640; 424/094.650; 424/094.660; 424/094.670;  
424/450.000; 424/489.000  
NCL NCLM: 530/380.000  
NCLS: 424/078.040; 424/094.640; 424/094.650; 424/094.660; 424/094.670;  
424/450.000; 424/489.000; 530/350.000; 530/381.000; 530/412.000  
IC [7]  
ICM: A61K035-14  
ICS: A61K038-16; A61K009-127; C07K014-00; C07K017-00  
EXF 424/78.04; 424/94.64; 424/94.65; 424/94.66; 424/94.67; 424/450; 424/489;  
514/912; 514/12; 530/350; 530/380; 530/381; 530/412  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 22 USPATFULL

AN 2002:202125 USPATFULL  
TI Method for inhibiting inflammatory disease  
IN Tuse, Daniel, Menlo Park, CA, United States  
Hiebert, Charles, Sunnyvale, CA, United States  
Laderoute, Keith R., Palo Alto, CA, United States  
Waleh, Nahid, Palo Alto, CA, United States  
PA Large Scale Biology Corp., Vacaville, CA, United States (U.S.  
corporation)  
SRI International, Menlo Park, CA, United States (U.S. corporation)  
PI US 6433012 AI 20020813  
AI US 2000-656144 200000906 (9)  
RLI Continuation-in-part of Ser. No. US 1999-274813, filed on 22 Mar 1999,  
now patented, Pat. No. US 6156407  
PRAI US 1998-79313P 19980325 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1760  
INCL INCLM: 514/532.000  
INCLS: 514/535.000; 514/543.000; 428/450.000  
NCL NCLM: 514/532.000  
NCLS: 428/450.000; 514/535.000; 514/543.000  
IC [7]  
ICM: A61K031-12  
EXF 514/532; 514/535; 514/543; 424/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 22 USPATFULL  
AN 2002:191539 USPATFULL  
TI Full-length human cDNAs encoding potentially secreted proteins  
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE  
Bouquelaret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE  
PI US 2002102604 AI 20020801  
AI US 2000-731872 AI 20001207 (9)  
PRAI US 1999-169629P 19991208 (60)  
US 2000-187470P 200000306 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 28061  
INCL INCLM: 435/007.100  
INCLS: 536/023.100; 530/350.000  
NCL NCLM: 435/007.100  
NCLS: 536/023.100; 530/350.000  
IC [7]  
ICM: G01N033-53  
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 22 USPATFULL  
AN 2002:92863 USPATFULL  
TI Noninvasive measurement of chemical substances  
IN Abreu, Marcio Marc, North Haven, CT, UNITED STATES  
PI US 2002049389 AI 20020425  
US 6544193 B2 20030408  
AI US 2001-790653 AI 20010223 (9)  
RLI Continuation of Ser. No. US 2000-517124, filed on 29 Feb 2000, GRANTED,  
Pat. No. US 6312393 Continuation of Ser. No. US 1998-184127, filed on 2  
Nov 1998, GRANTED, Pat. No. US 6120460 Continuation of Ser. No. US  
1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139  
DT Utility  
FS APPLICATION  
LN.CNT 11219

INCL INCLM: 600/358.000  
INCLS: 600/318.000  
NCL NCIM: 600/358.000  
IC [7]  
ICM: A61B003-00  
ICCS: A61B003-00

L9 ANSWER 8 OF 22 USPATFULL  
AN 2002:90848 USPATFULL  
TI Method and apparatus for signal transmission and detection using a contact device  
IN Abreu, Marcio Marc, North Haven, CT, UNITED STATES  
PI US 2002049374 AI 20020425  
US 6423001 B2 20020723  
AI US 2001-827325 AI 20010436 (9)  
RLI Continuation of Ser. No. US 2000-575621, filed on 22 May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US 1999-274882, filed on 28 Mar 1999, GRANTED, Pat. No. US 6123668 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139  
DT Utility  
FS APPLICATION  
LN.CNT 5891  
INCL INCLM: 600/405.000  
INCLS: 600/399.000; 600/400.000; 600/404.000  
NCL NCIM: 600/405.000  
NCLS: 600/399.000; 600/400.000; 600/404.000; 600/561.000  
IC [7]  
ICM: A61B003-16

L9 ANSWER 10 OF 22 USPATFULL  
AN 2002:92280 USPATFULL  
TI Novel antioxidants  
IN Avery, Mitchell Allen, Oxford, MS, UNITED STATES  
Pershadsingh, Harrihar A., Bakersfield, CA, UNITED STATES  
PI US 2002048798 AI 20020425  
AI US 2001-809518 AI 20010314 (9)  
PRAI US 2000-189514P 200000315 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4281  
INCL INCLM: 435/183.000  
INCLS: 536/008.000; 549/039.000  
NCL NCIM: 435/183.000  
NCLS: 536/008.000; 549/039.000  
IC [7]  
ICM: C07H007-06  
ICCS: C07D339-04; C12N009-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 22 USPATFULL  
AN 2001:196313 USPATFULL  
TI Contact device for placement in direct apposition to the conjunctive of the eye  
IN Abreu, Marcio Marc A. M., 3304 Dixwell Ave., North Haven, CT, United States 06473  
PI US 6312393 B1 20011106  
AI US 2000-517124 200000229 (9)  
RLI Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, now patented, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139

PT Utility  
FS Granted  
LN.CNT 7988  
INCL INCLM: 600/558.000  
NCL NCLM: 600/558.  
IC [7]  
ICM: A61B003-00  
EXF 600/399; 600/400; 600/404; 600/405; 600/558; 600/584; 604/19; 604/17

LS ANSWER 13 OF 22 USPATFULL  
AN 2001:51168 USPATFULL  
TI Apparatus for signal transmission and detection using a contact device for physical measurement on the eye  
IN Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT, United States 06473  
PI US 6213643 R1 20010410  
AI US 2000-575621 20000522 (9)  
RLI Continuation of Ser. No. US 1999-274882, filed on 23 Mar 1999, now patented, Pat. No. US 6123668 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, now patented, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139, issued on 3 Nov 1998  
PT Utility  
FS Granted  
LN.CNT 5868  
INCL INCLM: 600/405.000  
INCLS: 600/399.000; 600/400.000; 600/404.000  
NCL NCLM: 600/405.000  
NCLS: 600/399.000; 600/400.000; 600/404.000  
IC [7]  
ICM: A61B003-16  
EXF 600/399; 600/400; 600/404; 600/405; 600/558; 600/584; 604/19

LS ANSWER 13 OF 22 USPATFULL  
AN 2000:157456 USPATFULL  
TI Methods for inhibiting angiogenesis  
IN Tuse, Daniel, Menlo Park, CA, United States  
Hiebert, Charles, Sunnyvale, CA, United States  
Laderoute, Keith R., Palo Alto, CA, United States  
Waleh, Nahid, Palo Alto, CA, United States  
PA Large Scale Biology Corporation, Vacaville, CA, United States (U.S. corporation)  
SRI International, Menlo Park, CA, United States (U.S. corporation)  
PI US 6150407 20001121  
AI US 1999-274813 19990322 (9)  
PT Utility  
FS Granted  
LN.CNT 1548  
INCL INCLM: 514/532.000  
INCLS: 514/535.000; 514/543.000; 424/450.000; 600/562.000  
NCL NCLM: 514/532.000  
NCLS: 424/450.000; 514/535.000; 514/543.000; 600/562.000  
IC [7]  
ICM: A61K031-235  
ICS: A61K031-24; A61K031-19  
EXF 424/450; 514/532; 514/535; 514/543; 600/562  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LS ANSWER 14 OF 22 USPATFULL  
AN 2000:137825 USPATFULL  
TI Enzyme orthokeratology  
IN Harris, Donald H., Laguna Niguel, CA, United States

May, Charles, San Diego, CA, United States  
Karageozian, Hampar, San Juan Capistrano, CA, United States  
PA ISTA Pharmaceutical, Inc., Irvine, CA, United States (U.S. corporation)  
PI US 6132735 199001017  
AI US 1047-032974 19971915 +  
RLI Division of Ser. No. US 1990 712967, filed on 12 Sep 1990 which is a continuation of Ser. No. US 1994-011749, filed on 18 Jul 1994, now patented, Pat. No. US 5626865 which is a continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5274051  
PRAI WO 1992-US8791 19921015  
DT Utility  
FS Granted  
LN.CNT 1531  
INCL INCLM: 424/400.000  
INCLS: 424/429.000; 514/839.000  
NCL NCLM: 424/400.000  
NCLS: 424/429.000; 514/839.000  
IC [7]  
ICM: A61K009-00  
EXF 424/429; 424/400; 514/839  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 22 USPATFULL  
AN 2000:127705 USPATFULL  
TI Method and apparatus for signal transmission and detection using a contact device  
IN Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT, United States 06473  
PI US 6123668 20000926  
AI US 1999-274882 19990323 (9)  
RLI Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998 which is a continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139, issued on 3 Nov 1998  
DT Utility  
FS Granted  
LN.CNT 5933  
INCL INCLM: 600/405.000  
INCLS: 600/399.000; 600/400.000; 600/404.000  
NCL NCLM: 600/405.000  
NCLS: 600/399.000; 600/400.000; 600/404.000  
IC [7]  
ICM: A61B003-16  
EXF 600/558; 600/584; 600/405; 600/404; 600/400; 600/399; 604/19

L9 ANSWER 16 OF 22 USPATFULL  
AN 2000:124240 USPATFULL  
TI Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions  
IN Abreu, Marcio Marc, 5709 Elmer St., No. 102, Pittsburgh, PA, United States 15232  
PI US 6120460 20000919  
AI US 1998-184127 19981102 (9)  
RLI Continuation of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139  
DT Utility  
FS Granted  
LN.CNT 5864  
INCL INCLM: 600/558.000  
INCLS: 600/405.000  
NCL NCLM: 600/558.000  
NCLS: 600/405.000

IC [7]  
ICM: A61B005-00  
EXF 600/558; 600/584; 600/408; 604/17

LS ANSWER 17 OF 22 USPATFULL  
AN 1998:91693 USPATFULL  
TI Enzyme orthokeratology  
IN Harris, Donald H., Laguna Niguel, CA, United States  
PA Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S.  
corporation)  
PI US 5788957 19980804  
AI US 1996-712967 19960912 (8)  
RLI Continuation of Ser. No. US 1994-211749, filed on 18 Jul 1994, now  
patented, Pat. No. US 5626865 which is a continuation-in-part of Ser.  
No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US  
5270051  
DT Utility  
FS Granted  
LN.CNT 1703  
INCL INCLM: 424/078.040  
INCLS: 424/094.620; 424/423.000; 424/427.000; 424/428.000; 424/429.000;  
514/912.000; 435/180.000; 435/185.000; 435/201.000; 623/004.000;  
623/005.000  
NCL NCLM: 424/078.040  
NCLS: 424/094.620; 424/423.000; 424/427.000; 424/428.000; 424/429.000;  
435/180.000; 435/182.000; 435/201.000; 514/912.000; 623/005.110;  
623/906.000  
IC [6]  
ICM: A61F002-14  
ICS: A61K037-54; C12N009-26; C12N011-08  
EXF 424/94.62; 424/28.08; 424/423; 424/427; 424/428; 424/429; 514/912;  
435/108; 435/182; 435/201; 623/4; 623/5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LS ANSWER 18 OF 22 USPATFULL  
AN 97:38211 USPATFULL  
TI Enzyme-orthokeratology  
IN Harris, Donald H., Laguna Niguel, CA, United States  
May, Charles, San Diego, CA, United States  
Karageozian, Hampar, San Juan Capistrano, CA, United States  
PA Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S.  
corporation)  
PI US 5626865 19970506  
WO 9307840 19930429  
AI US 1994-211749 19940718 (8)  
WO 1992-US8791 19921015  
19940718 PCT 371 date  
19940718 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991,  
now patented, Pat. No. US 5270051  
DT Utility  
FS Granted  
LN.CNT 1787  
INCL INCLM: 424/427.000  
INCLS: 424/094.620; 424/423.000; 424/428.000; 424/429.000; 424/078.040;  
514/912.000; 623/004.000; 623/005.000  
NCL NCLM: 424/427.000  
NCLS: 424/078.040; 424/094.620; 424/423.000; 424/428.000; 424/429.000;  
514/912.000; 623/005.110  
IC [6]  
ICM: A61F002-14  
ICS: A61F009-013; A61K038-48

EXF 424/427; 424/94.62; 424/423; 424/428; 424/429; 424/78.04; 514/912;  
623/4; 623/5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 22 USPATFULL  
AN 97:25004 USPATFULL  
TI Method and composition for treating the skin  
IN Mohammadi, Fatemeh, 114<sup>th</sup> Parklawn Dr., Lexington, KY, United States  
40517  
Nosek, Dagmar, 200 Patchen Dr., Apt. 118, Lexington, KY, United States  
40517  
PI US 5614489 19970325  
AI US 1995-450430 19950525 (8)  
DT Utility  
FS Granted  
LN.CNT 512  
INCL INCLM: 514/002.000  
INCLS: 514/200.000; 514/844.000; 514/847.000; 512/001.000  
NCL NCLM: 514/002.000  
NCLS: 512/001.000; 514/200.000; 514/844.000; 514/847.000  
IC [6]  
ICM: A61K038-00  
ICS: A61K031-545  
EXF 514/2; 514/200; 514/844; 514/847; 512/1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 22 USPATFULL  
AN 93:76417 USPATFULL  
TI Preparation of a polymeric hydrogel containing micropores and macropores  
for use as a cell culture substrate  
IN Anderson, David M., 337 Squire Hall Suny, Buffalo, NY, United States  
14214  
PI US 5244799 19930914  
AI US 1991-809259 19911217 (7)  
RLI Continuation of Ser. No. US 1990-574506, filed on 23 Aug 1990, now  
abandoned which is a continuation of Ser. No. US 1989-323616, filed on  
14 Mar 1989, now abandoned which is a continuation-in-part of Ser. No.  
US 1988-292615, filed on 30 Dec 1988, now abandoned which is a  
continuation-in-part of Ser. No. US 1987-52713, filed on 20 May 1987,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 595  
INCL INCLM: 435/240.230  
INCLS: 424/487.000; 435/174.000; 435/180.000; 523/106.000; 525/937.000;  
526/328.000; 528/310.000  
NCL NCLM: 435/397.000  
NCLS: 424/487.000; 435/174.000; 435/180.000; 523/106.000; 525/937.000;  
526/328.000; 528/310.000  
IC [5]  
ICM: C12N005-00  
ICS: C12N011-08; C08F020-10; C08G069-08  
EXF 435/174; 435/177; 435/180; 435/182; 435/240.23; 424/484; 424/487;  
523/105; 523/106; 523/113; 525/937; 521/50; 521/64; 521/65; 526/328;  
528/310; 204/194; 204/403  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 22 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1159941 EUROPATFULL ED 20011213 EW 200149 FS OS

**TIEN** Formulations for use in enzyme-orthokeratology.  
**TIDE** Zusammensetzung zur Verwendung in der Enzymkeratologie.  
**TIFF** Formulations pour usage dans l'orthokeratologie enzymatique.  
**IN** Harris, Donald R., 1303 Avonado, Suite 100, Newport Beach, CA 92680, US;  
 May, Charles, 311 Fourth Avenue, San Diego, CA 92101, US;  
 Karageozian, Hampar, 31001 Marbella Vista, San Juan Capistrano, CA  
 92675, US  
**PA** Ista Pharmaceuticals, Inc., 1414 Muirlands Drive, La Jolla, CA 92097, US  
**NO** Wild-EPZ-2001-H49-TB  
**DS** R AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IE; R IT; R LI;  
 R NL; R SE  
**PIT** EPA2 EUROPÄISCHE PATENTANMELDUNG  
**PI** EP 1159941 A2 20011205  
**OD** 20011205  
**AI** EP 2001203285 19921015  
**PRAI** US 1991 776211 19911015  
**RLI** EP 608341 DIV  
**IC** ICM A61F009-00  
 ICS A61F002-14

L9 ANSWER 22 OF 22 EUROPATFULL COPYRIGHT 2003 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 608341 EUROPATFULL ED 20020404 EW 200213 FS PS  
 TIEN ENZYME-ORTHOKERATOLOGY.  
 TIDE ENZYMORTHOKERATOLOGIE.  
 TIFR ORTHOKERATOLOGIE ENZYMATIQUE.  
 IN HARRIS, Donald, H., 200 Newport Center Drive, Suite 110, Newport Beach,  
     CA 92660, US;  
     MAY, Charles, 3311 Fourth Avenue, San Diego, CA 92103, US;  
     KARAGEOZIAN, Hampar, 31021 Marbella Vista, San Juan Capistrano, CA  
     92675, US  
 PA Ista Pharmaceuticals, Inc., 1414 Muirlands Drive, La Jolla, CA 92307, US  
 SO Wila-EPS-2002-H13-T2  
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;  
     R NL; R SE  
 PIT EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale Anmeldung)  
 PI EP 608341 B1 20020327  
 OD 19940803  
 AI EP 1992-922291 19921015  
 PRAI US 1991-776211 19911015  
 FLI WO 92-US8791 921015 INTAKZ  
     WO 9307840 930429 INTPNR  
 REP DE 2308144 A DE 2426757 A  
     DE 861753 C US 1929228 A  
     US 3416530 A US 3485244 A  
     US 3760807 A US 4540417 A  
 IC ICM A61F009-00

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
138.67	138.65

FILE 'STNGUIDE' ENTERED AT 13:22:53 ON 24 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 20, 2003 (20030620/UP).

· d his

FILE 'HOME' ENTERED AT 12:36:44 ON 24 JUN 2003.

FILE 'CAPLUS, UNPATFULL, EURPATFULL, NAPIC, MERLINE, BIOSIN, EMRASE' ENTERED AT 12:37:21 ON 24 JUN 2003

L1        1437 S CARRAGEENAN# AND ANTIMICROBIAL?  
L2        323931 S (RETINO? OR VITAMIN(W)A OR VIT(W)A)  
L3        6359 S L2 AND CORNEA?  
L4        2411 S L3 AND EPITHELI?  
L5        662 S L4 AND (DRUG DELIVERY)  
L6        640 S L5 AND (DROP# OR MIST OR GEL OR OINTMENT OR SOLUTION)  
L7        69 S L6 AND (CONTACT LENS)  
L8        69 S L7 AND EPITHEL?  
L9        22 S L8 AND INTEGRITY

FILE 'STNGUIDE' ENTERED AT 13:22:53 ON 24 JUN 2003

=> s 18 and (corneal epithel?)  
    0 RETINO?  
    0 VITAMIN  
    222 A  
        0 VITAMIN(W) A  
        0 VIT  
    222 A  
        0 VIT(W) A  
        0 CORNEA?  
        0 EPITHELI?  
    32 DRUG  
        6 DELIVERY  
        2 DRUG DELIVERY  
            (DRUG(W) DELIVERY)  
    0 DROP#  
    0 MIST  
    0 GEL  
    0 OINTMENT  
    1 SOLUTION  
    10 CONTACT  
        0 LENS  
        0 CONTACT LENS  
            (CONTACT(W) LENS)  
    0 EPITHEL?  
    0 CORNEAL  
    0 EPITHEL?  
    0 CORNEAL EPITHEL?  
            (CORNEAL(W) EPITHEL?)  
L10        0 L8 AND (CORNEAL EPITHEL?)

=> s 18 and differentiation  
    0 RETINO?  
    0 VITAMIN  
    222 A  
        0 VITAMIN(W) A  
        0 VIT  
    222 A  
        0 VIT(W) A  
        0 CORNEA?  
        0 EPITHELI?  
    32 DRUG  
        6 DELIVERY

- 2 DRUG DELIVERY
  - DRUG (W) DELIVERY
- 0 DROPS #
- 0 MIST
- 0 GEL
- 0 OINTMENT
- 1 SOLUTION
- 1 CONTACT
- 0 LENS
- 0 CONTACT LENS
  - (CONTACT (W) LENS)
- 0 EPITHEL?
- 0 DIFFERENTIATION
- 0 L8 AND DIFFERENTIATION

=> file caplus uspatfull japio europatfull medline biosis embase  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.90 139.78

FILE 'CAPLUS' ENTERED AT 13:31:44 ON 24 JUN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:31:44 ON 24 JUN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 13:31:44 ON 24 JUN 2003  
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 13:31:44 ON 24 JUN 2003  
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 13:31:44 ON 24 JUN 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

卷之三

(FILED HOME ENTERED AT 12:56:44 ON 24 JUN 2003)

THE CAPEX, CIRAPIPOL, CIRPAPOL, CAPTE, MEDTINE, BIOSIS, EMBASE  
ENTERED AT 12:37:21 ON 24 JUN 2003

1437 S. CABBAGEBUSH# AND ANTIMICROBIAL?

I-1 3-(BETINO<sub>2</sub>)OB-VITAMIN(W)A OB VIT(W)A

L3 63559 S L2 AND CORNEA?

L<sub>4</sub> AND L<sub>3</sub> AND CORTEX L<sub>3</sub> AND EPITHELIAL

#### **L5** DRUGS AND DRUG DELIVERY

L6 640 S L5 AND (DROP# OR MISSING OR EXEL OR CIN)

L7 S 69 S L6 AND (CONTACT LENS)

## L8 S<sup>9</sup> S L7 AND EPITHEL?

L9 S. L8 AND INTEGRITY

FILE 'STNGUIDE' ENTERED AT 13:22:53 ON 24 JUN 20

L10 O S L8 AND (CORNEAL EPITHEL?)

## L11 O S LS AND DIFFERENTIATION

FILE 'CAPLUS, USPATFULL, CAPIS, EUROPATFULL, MEDLINE, BIOSIS, EMBASE'  
ENTERED AT 13:31:44 ON 24 JUN 2003

L12 ANSWER 1 OF 18 USPATFULL  
L12 IS 18 AND CORNEAL EPITHELIUM.

L12 112 1-18 ibib abs

L12 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:487371 CAPLUS  
DOCUMENT NUMBER: 137:52396  
TITLE: Method for enhancing integrity of **epithelium**  
**retinoic** acid  
INVENTOR(S): Lever, Andrea; Smerbeck, Richard V.  
PATENT ASSIGNEE(S): Bausch & Lomb Incorporated, USA  
SOURCE: PCT Int. Appl., 13 pp.  
CODEN: PIXMD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049613	A2	20020627	WO 2001-US46499	20011203
WO 2002049613	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002032487	A5	20020701	AU 2002-32487	20011203
US 2002115720	A1	20020822	US 2001-23351	20011217
PRIORITY APPLN. INFO.:			US 2000-256713P	P 20001219
			WO 2001-US46499	W 20011203

AB A method for improving the integrity of the **corneal epithelium** by introducing into the eye an effective amt. of a ophthalmically compatible **retinoid** sufficient to enhance the integrity of the **corneal epithelium**. For example, an ophthalmic **ointment** was formulated for treating superior **epithelial** arcuate lesions (SEALs) and/or **corneal** infiltrates contg. **retinoic** acid 0.05 mg/g, mineral oil 100 mg/g, and white petrolatum 899.9 mg/g.

L12 ANSWER 2 OF 18 USPATFULL  
ACCESSION NUMBER: 2003:100378 USPATFULL  
TITLE: Method and apparatus for signal transmission and detection using a contact device  
INVENTOR(S): Abreu, Marcio Marc, North Haven, CT, UNITED STATES

NUMBER	KIND	DATE
US 2003069489	A1	20030410
US 2002-189778	A1	20020708 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-827325, filed on 6 Apr 2001, GRANTED, Pat. No. US 6423001 Continuation of Ser. No. US 2000-575621, filed on 22 May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US 1999-274883,	

filed on 23 Mar 1999, GRANTED, Pat. No. US 6123668  
Continuation of Ser. No. US 1998-184127, filed on 2 Nov  
1998, GRANTED, Pat. No. US 6120460 Continuation-in-part  
of Ser. No. US 1996-707508, filed on 4 Sep 1996,  
GRANTED, Pat. No. US 5513137

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: JACOBSON HOLMAN PLLC, 400 SEVENTH STREET N.W., SUITE  
600, WASHINGTON, DC, 20004  
NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 35 Drawing Page(s)  
LINE COUNT: 5863

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis.

L12 ANSWER 3 OF 18 USPATFULL  
ACCESSION NUMBER: 2003:81451 USPATFULL  
TITLE: Use of **corneal** hardening agents in  
enzymeorthokeratology  
INVENTOR(S): Karageozian, Hamper, San Juan Capistrano, CA, United  
States  
Park, John Y., Santa Ana, CA, United States  
Karageozian, Vicken, San Juan Capistrano, CA, United  
States  
Baker, Phillip, Walnut Creek, CA, United States  
Nesburn, Anthony, Malibu, CA, United States  
PATENT ASSIGNEE(S): ISTA Pharmaceuticals, Inc., Irvine, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6537545	B1	20030325
APPLICATION INFO.:	US 2000-656849		20000907 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US5135, filed on 9 Mar 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-77339P	19980309 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Lankford, Jr., Leon B.	
ASSISTANT EXAMINER:	Davis, Ruth A.	
LEGAL REPRESENTATIVE:	Knobbe Martens Olson & Bear LLP	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2681	

AB An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the **cornea** is accomplished by administering a **corneal**

hardening amount of a **corneal** hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid **contact lens** or a series of lenses having a concave curvature that will correct a refractive error. The **cornea** rapidly reshapes its convex curvature to the concave curvature of the **contact lens**, rendering the eye emmetropic. The **cornea** is permitted to "harden" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

L12 ANSWER 4 OF 18 USPATFULL

ACCESSION NUMBER: 2002:224703 USPATFULL

TITLE: Methods and compositions for the treatment of keratoconus using protease inhibitors

INVENTOR(S): Quay, Steven C., Edmonds, WA, United States

PATENT ASSIGNEE(S): K-Quay Enterprises, LLC, Edmonds, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444791	Bl	20020903
APPLICATION INFO.:	US 2000-695774		20001024 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-161879P	19991027 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Kam, Chih-Min	
LEGAL REPRESENTATIVE:	Woodcock Washburn LLP	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2800	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for treating **corneal** diseases mediated by elevated protease activity include ocular administration of protease inhibitors. One or more protease inhibitors selected from an aspartic, serine, cysteine, or metallo-protease inhibitor are administered to an ocular fluid, surface, or tissue, preferably by topical administration, to inhibit proteolytic activity associated with a **corneal** disease or condition, for example keratoconus. Antiproteolytic formulations of the invention may include carriers that prolong the retention and/or enhance delivery of the protease inhibitor. These formulations can also include other therapeutic agents such as antiinflammatory or antibiotic drugs. In preferred aspects of the invention, antiproteolytic formulations are administered during periods of closed eye tear production. Also provided within the invention are implant devices for **corneal** delivery of a protease inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 18 USPATFULL

ACCESSION NUMBER: 2002:126055 USPATFULL

TITLE: Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide

INVENTOR(S): Karagozian, Hampar L., San Juan Capistrano, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002064585 A1 20020530  
APPLICATION INFO.: US 2001-911638 A1 20010723 (9)  
RELATED APPLN. INFO.: Continuation-in part of Ser. No. US 1999-412174, filed  
on 4 Oct 1999, UNKNOWN  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STETINA BRUNDA GARRET & BRUCKER, 75 ENTERPRISE, SUITE  
250, ALISO VIEJO, CA, 92656  
NUMBER OF CLAIMS: 42  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1186

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An anti-microbial liquid ophthalmic composition for direct application onto an eye of a living being. The composition includes from about 0.02 wt. to about 0.20 wt. chlorite compound and from about 0.005 wt. to about 0.01 wt. peroxy compound, at a pH between about 7.0 and 7.8. Preferably, the chlorite compound is a metal chlorite where the metal is chosen from the group consisting of sodium, potassium, calcium, and magnesium, while the peroxy compound is hydrogen peroxide. Also included are methods for treating an eye infection through application of the composition to the eye, and for cleansing a **contact lens** in place on an eye through application of the composition to the lens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 18 USPATFULL

ACCESSION NUMBER: 2002:92863 USPATFULL  
TITLE: Noninvasive measurement of chemical substances  
INVENTOR(S): Abreu, Marcio Marc, North Haven, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049389	A1	20020425
	US 6544193	B2	20030408
APPLICATION INFO.:	US 2001-790653	A1	20010223 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-517124, filed on 29 Feb 2000, GRANTED, Pat. No. US 6312393 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JACOBSON, PRICE, HOLMAN & STERN, PROFESSIONAL LIMITED LIABILITY COMPANY, THE JENIFER BUILDING, 400 SEVENTH STREET, N. W., WASHINGTON, DC, 20004		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	84 Drawing Page(s)		
LINE COUNT:	1121 <sup>g</sup>		
AB	Utilization of a contact device placed on the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the conjunctiva and in the tear film. A transensor mounted in the contact device laying on the <b>cornea</b> or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye		

including non-invasive blood analysis. The system utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by wires or radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like.

L12 ANSWER 7 OF 18 USPATFULL

ACCESSION NUMBER: 2002:92848 USPATFULL

TITLE: Method and apparatus for signal transmission and detection using a contact device

INVENTOR(S): Abreu, Marcio Marc, North Haven, CT, UNITED STATES

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION:	US 2002049374	A1	20020425
---------------------	---------------	----	----------

	US 6423001	B2	20020723
--	------------	----	----------

APPLICATION INFO.:	US 2001-827325	A1	20010406 (9)
--------------------	----------------	----	--------------

RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-575621, filed on 22 May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US 1999-274882, filed on 23 Mar 1999, GRANTED, Pat. No. US 6123668 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139
-----------------------	---

DOCUMENT TYPE:	Utility
----------------	---------

FILE SEGMENT:	APPLICATION
---------------	-------------

LEGAL REPRESENTATIVE:	JACOBSON, PRICE, HOLMAN & STERN, PROFESSIONAL LIMITED LIABILITY COMPANY, THE JENIFER BUILDING, 400 SEVENTH STREET, N. W., WASHINGTON, DC, 20004
-----------------------	---

NUMBER OF CLAIMS:	20
-------------------	----

EXEMPLARY CLAIM:	1
------------------	---

NUMBER OF DRAWINGS:	35 Drawing Page(s)
---------------------	--------------------

LINE COUNT:	5891
-------------	------

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the cornea or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled

individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L12 ANSWER 8 OF 18 USPATFULL

ACCESSION NUMBER: 2001:202646 USPATFULL  
TITLE: Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists  
INVENTOR(S): Pershad Singh, Harrihar A., Bakersfield, CA, United States  
PATENT ASSIGNEE(S): Levy, Daniel E., San Carlos, CA, United States  
Photogenesis, Inc., Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316465	B1	20011113
APPLICATION INFO.:	US 1999-342381		19990628 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-90937P	19980627 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Williamson, Michael A.	
LEGAL REPRESENTATIVE:	Brinks, Hofer, Gilson & Lione	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1661	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating diseases of ocular tissues expressing the nuclear receptor PPAR.gamma., by inhibiting the inflammatory response, the neovascularization and angiogenesis, and programmed cell death (apoptosis) in these target tissues, comprising administering to a human or animal in need of treatment an effective amount of a compound that modifies the activity of PPAR.gamma., or pharmaceutically acceptable salts and solvates thereof.

Novel compounds and methods for their synthesis are provided, including a compound having the general structure: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 18 USPATFULL

ACCESSION NUMBER: 2001:196313 USPATFULL  
TITLE: Contact device for placement in direct apposition to the conjunctive of the eye  
INVENTOR(S): Abreu, Marcio Marc A. M., 3304 Dixwell Ave., North Haven, CT, United States 06473

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6312393	B1	20011106

APPLICATION INFO.: US 2000-517124 200006229 (9)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-184127, filed on 2 Nov  
1998, now patented, Pat. No. US 6120460  
Continuation-in-part of Ser. No. US 1996-707598, filed  
on 4 Sep 1996, now patented, Pat. No. US 583153  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Hindenburg, Max  
LEGAL REPRESENTATIVE: Jacobson Holman, PLLC  
NUMBER OF CLAIMS: 62  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 158 Drawing Figure(s); 57 Drawing Page(s)  
LINE COUNT: 7988

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye (conjunctiva) and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a **drug delivery** system and therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye (conjunctiva), with the data being preferable transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L12 ANSWER 10 OF 18 USPATFULL  
ACCESSION NUMBER: 2001:51168 USPATFULL  
TITLE: Aparatus for signal transmission and detection using a contact device for physical measurement on the eye  
INVENTOR(S): Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT,  
United States 06473

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6213943	B1	20010410
APPLICATION INFO.:	US 2000-575621		20000522 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-274882, filed on 23 Mar 1999, now patented, Pat. No. US 6123668 Continuation of Ser. No. US 1998-184127, filed on 2 Nov		

1998, now patented, Pat. No. US 6120460  
Continuation-in-part of Ser. No. US 1996-707508, filed  
on 4 Sep 1996, now patented, Pat. No. US 5830139,  
issued on 3 Nov 1998

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Hindenburg, Max  
LEGAL REPRESENTATIVE: Jacobson, Price, Holman & Stern, PLLC  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 104 Drawing Figure(s); 35 Drawing Page(s)  
LINE COUNT: 5868

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

I.12 ANSWER 11 CF 18 USPATFULL  
ACCESSION NUMBER: 2000:137825 USPATFULL  
TITLE: Enzyme-orthokeratology  
INVENTOR(S): Harris, Donald H., Laguna Niguel, CA, United States  
May, Charles, San Diego, CA, United States  
Karageozian, Hampar, San Juan Capistrano, CA, United States  
PATENT ASSIGNEE(S): ISTA Pharmaceutical, Inc., Irvine, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6132735		20001017
APPLICATION INFO.:	US 1997-932974		19970918 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-712967, filed on 12 Sep 1996 which is a continuation of Ser. No. US		

1994-211748, filed on 18 Jul 1994, now patented, Pat. No. US 5626865 which is a continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1992-US8791	19921015
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kight, John	
ASSISTANT EXAMINER:	Faulkner, D.	
LEGAL REPRESENTATIVE:	Knöbbe, Martens, Olson & Bear, LLP	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	1531	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the **corneal** tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the **cornea**. The **cornea** is thereafter fitted with a rigid **contact lens** or a series of lenses which have a concave curvature that will correct a refractive error. The softened **cornea** then rapidly reshapes its convex curvature to the concave curvature of the **contact lens** or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the **cornea**, and the **cornea** "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 18 USPATFULL  
ACCESSION NUMBER: 2000:127705 USPATFULL  
TITLE: Method and apparatus for signal transmission and detection using a contact device  
INVENTOR(S): Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT, United States 06473

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6123668		20000926
APPLICATION INFO.:	US 1999-274882		19990323 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998 which is a continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139, issued on 3 Nov 1998		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Hindenburg, Max
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern, PLLC
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	104 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT:	5933

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the

like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L12 ANSWER 13 OF 18 USPATFULL  
 ACCESSION NUMBER: 2000:124240 USPATFULL  
 TITLE: Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions  
 INVENTOR(S): Abreu, Marcio Marc, 5709 Elmer St., No. 102, Pittsburgh, PA, United States 15232

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6120460		20000919
APPLICATION INFO.:	US 1998-184127		19981102 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hindenburg, Max		
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern, PLLC		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	102 Drawing Figure(s); 35 Drawing Page(s)		
LINE COUNT:	5864		

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to

activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radioc telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of evulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L12 ANSWER 14 OF 18 USPATFULL

ACCESSION NUMBER: 1998:91593 USPATFULL  
TITLE: Enzyme-orthokeratology  
INVENTOR(S): Harris, Donald H., Laguna Niguel, CA, United States  
PATENT ASSIGNEE(S): Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5788957		19980804
APPLICATION INFO.:	US 1996-712967		19960912 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-211749, filed on 18 Jul 1994, now patented, Pat. No. US 5626865 which is a continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Krass, Frederick  
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear, LLP  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 11 Drawing Page(s)  
LINE COUNT: 1703

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the **corneal** tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the **cornea**. The **cornea** is thereafter fitted with a rigid **contact lens** or a series of lenses which have a concave curvature that will correct a refractive error. The softened **cornea** then rapidly reshapes its convex curvature to the concave curvature of the **contact lens** or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the **cornea**, and the **cornea** "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 18 USPATFULL  
 ACCESSION NUMBER: 97:38211 USPATFULL  
 TITLE: Enzyme-orthokeratology  
 INVENTOR(S): Harris, Donald H., Laguna Niguel, CA, United States  
 May, Charles, San Diego, CA, United States  
 Karageozian, Hampar, San Juan Capistrano, CA, United States  
 PATENT ASSIGNEE(S): Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5626865		19970506
	WO 9307840		19930429
APPLICATION INFO.:	US 1994-211749		19940718 (8)
	WO 1992-US8791		19921015
			19940718 PCT 371 date
			19940718 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Krass, Frederick		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	1787		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the **corneal** tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the **cornea**. The **cornea** is thereafter fitted with a rigid **contact lens** or a series of lenses which have a concave curvature that will correct a refractive error. The softened **cornea** then rapidly reshapes its convex curvature to the concave curvature of the **contact lens** or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the **cornea**, and the **cornea** "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 16 OF 18 USPATFULL  
 ACCESSION NUMBER: 93:76417 USPATFULL  
 TITLE: Preparation of a polymeric hydrogel containing micropores and macropores for use as a cell culture substrate  
 INVENTOR(S): Anderson, David M., 337 Squire Hall Suny, Buffalo, NY, United States 14214

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5244799		19930914
APPLICATION INFO.:	US 1991-809259		19911217 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-574506, filed on 23 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-323616, filed on 14 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-292615, filed on 30 Dec 1988, now abandoned which		

is a continuation-in-part of Ser. No. US 1987-52713,  
filed on 20 May 1987, now abandoned

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Naff, David M.  
LEGAL REPRESENTATIVE: Blodgett & Blodgett  
NUMBER OF CLAIMS: 7  
EXEMPLARY CLAIM: 1  
LINE COUNT: 595

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hydrophilic substituent of a bicontinuous cubic phase in equilibrium is polymerized and the unpolymerized components subsequently removed and replaced with water, creating a hydrogel which is locally highly cross-linked but of high water content because of the presence of a periodic network of water-filled macropores superposed on the hydrogel matrix. The diameter of these "macropores" can be preselected between 20 Angstroms and several hundred Angstroms or even higher, and in general will be much larger than the "micropores" within the hydrogel portions of the final material. The material has high water content, good mechanical integrity and notch strength, high permeability to oxygen, and the pore size can be chosen to allow passage of molecules of pre-selected size. The material is useful as a cell culture substrate and in a **contact lens** and other biological and medical applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 17 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1159941 EUROPATFULL EW 200149 FS OS  
TITLE: Formulations for use in enzyme-orthokeratology.  
Zusammensetzung zur Verwendung in der Enzymkeratologie.  
Formulations pour usage dans l'orthokeratologie  
enzymatique.  
INVENTOR(S): Harris, Donald H., 1303 Avocado, Suite 100, Newport  
Beach, CA 92680, US;  
May, Charles, 3311 Fourth Avenue, San Diego, CA 92103,  
US;  
Karageozian, Hampar, 31021 Marbella Vista, San Juan  
Capistrano, CA 92675, US  
PATENT ASSIGNEE(S): Ista Pharmaceuticals, Inc., 1414 Muirlands Drive, La  
Jolla, CA 92307, US  
PATENT ASSIGNEE NO: 1643982  
AGENT: Hepworth, John Malcolm et al., Hepworth Lawrence Bryer &  
Bizley Merlin House, Falconry Court, Baker's Lane,  
Epping, Essex CM16 5DQ, GB  
31746  
AGENT NUMBER: 31746  
OTHER SOURCE: BEPA2001098 EP 1159941 A2 0031  
SOURCE: Wila-EPZ-2001-H49-T2b  
DOCUMENT TYPE: Patent  
LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch  
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R  
IE; R IT; R LI; R NL; R SE  
PATENT INFO.PUB.TYPE: EPA2 EUROPÄISCHE PATENTANMELDUNG  
PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 1159941	A2 20011205
APPLICATION INFO.:		20011205
	EP 2001-203285	19921015

PRIORITY APPLN. INFO.: US 1991-776211 19911015  
RELATED DOC. INFO.: EP 608341 PIV

L12 ANSWER 18 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 608341 EUROPATFULL EW 200213 FS PS  
TITLE: ENZYME-ORTHOKERATOLOGY.  
ENZYMORTHOKERATOLOGIE.  
ORTHOKERATOLOGIE ENZYMATIQUE.  
INVENTOR(S): HARRIS, Donald, H., 200 Newport Center Drive, Suite 110,  
Newport Beach, CA 92660, US;  
MAY, Charles, 3311 Fourth Avenue, San Diego, CA 92103,  
US;  
KARAGEOZIAN, Hampar, 31021 Marbella Vista, San Juan  
Capistrano, CA 92675, US  
PATENT ASSIGNEE(S): Ista Pharmaceuticals, Inc., 1414 Muirlands Drive, La  
Jolla, CA 92307, US  
PATENT ASSIGNEE NO: 1643982  
AGENT: Williams, Richard Andrew Norman et al., Hepworth  
Lawrence Bryer & Bizley Merlin House Falconry Court  
Bakers Lane, Epping, Essex CM16 5DQ, GB  
77491  
AGENT NUMBER:  
OTHER SOURCE: BEPB2002023 EP 0608341 B1 0028  
SOURCE: Wila-EPS-2002-H13-T2  
DOCUMENT TYPE: Patent  
LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch  
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R  
IE; R IT; R LI; R NL; R SE  
PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale  
Anmeldung)  
PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 608341	B1	20020327
APPLICATION INFO.:	EP 1992-922291		19940803
PRIORITY APPLN. INFO.:	US 1991-776211		19911015
RELATED DOC. INFO.:	WO 92-US8791		921015 INTAKZ
	WO 9307840		930429 INTPNR
REFERENCE PAT. INFO.:	DE 2308144 A	DE 2426757 A	
	DE 861753 C	US 1929228 A	
	US 3416530 A	US 3485244 A	
	US 3760807 A	US 4540417 A	